Project Grant K99CA304506
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$128K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) is funding the research project "Investigating the Cell Intrinsic and Extrinsic Mechanisms Governing Lung Cancer Cell Plasticity" at Columbia University. The $194,292 award over the period of Sep 1, 2024 to Aug 31, 2027 will support the investigator's work to quantitatively track cancer cell state transitions and delineate both cell-autonomous and non-cell-autonomous regulators of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
The National Cancer Institute (NCI) awarded a $128,736 Project Grant (CFDA 93.398 - Cancer Research Manpower) to the Icahn School of Medicine at Mount Sinai (ISMMS) on December 24, 2024. The purpose of this grant is to characterize the mechanisms by which lipid nanoparticles (LNPs) interact with dendritic cells (DCs) to enhance the efficacy of LNP-based cancer immunotherapies. Specifically, the project aims to 1) investigate changes in DC phenotype, function, and transcriptional profile upon...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $650,450 to the University of Southern California to develop a novel cancer immunotherapy using genetically engineered CD4+ T cells targeting the CT83 tumor antigen. The research aims to determine the mechanisms by which these engineered T cells eliminate lung cancer cells, produce GMP-grade master cell banks and viral particles, and develop a scalable...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $557,418 to The Trustees of Columbia University in the City of New York to conduct research on targeting SMARCA2 in SMARCA4-deficient lung cancers. The research aims to assess the effects of SMARCA2 degradation on SMARCA4-deficient lung cancer progression, elucidate the mechanisms underlying the relationship between SMARCA2 and SMARCA4, and develop effective combinatorial approaches...
The University of Louisville Office of Research & Innovation has been awarded a $402,401 Project Grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393). The grant will fund the development and investigation of a lung cancer vaccine based on exosomes derived from induced pluripotent stem cells (iPSCs) expressing the immunostimulatory cytokine GM-CSF (iPSC-EXO). The research aims to prevent lung tumorigenesis by triggering CD8+ T cell-mediated...
This $703,410 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University (NYU) School of Medicine to investigate molecular mechanisms underlying the transition from lung adenocarcinoma to squamous cell carcinoma, which can contribute to resistance to KRAS inhibitor therapies. The research aims to identify chromatin regulators that drive this lineage transition, and systematically decouple the...